Start SIP in
PEL
Performance
- Low
- ₹1,072
- High
- ₹1,140
- 52 Week Low
- ₹737
- 52 Week High
- ₹1,275
- Open Price₹1,140
- Previous Close₹1,098
- Volume620,263
Investment Returns
- Over 1 Month -7.61%
- Over 3 Month + 1.66%
- Over 6 Month + 22%
- Over 1 Year + 22.6%
Smart Investing Starts Here Start SIP with Piramal Enterprises for Steady Growth!
Piramal Enterprises Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -13.2
- PEG Ratio
- 0.1
- Market Cap Cr
- 24,960
- P/B Ratio
- 0.9
- Average True Range
- 38.96
- EPS
- 0
- Dividend Yield
- 0.9
- MACD Signal
- 11.64
- RSI
- 39.88
- MFI
- 40.8
Piramal Enterprises Financials
Piramal Enterprises Technicals
EMA & SMA
-
- Bullish Moving Average 6
-
- Bearish Moving Average 10
- 20 Day
- ₹1,153.24
- 50 Day
- ₹1,130.20
- 100 Day
- ₹1,083.85
- 200 Day
- ₹1,029.50
Resistance and Support
- R3 1,209.20
- R2 1,174.60
- R1 1,140.80
- S1 1,072.40
- S2 1,037.80
- S3 1,004.00
Piramal Enterprises Corporate Actions - Bonus, Splits, Dividends
Piramal Enterprises F&O
About Piramal Enterprises
Piramal Enterprises Limited is an Indian multinational pharmaceutical and financial services company based in Mumbai, Maharashtra. Founded by Ajay Piramal (who is also the Chairman), the company operates in the pharmaceuticals, financial services and real estate sector.
He founded the company in 1984 after he acquired a small-scale manufacturing unit from his father. Today, Piramal has more than 50 offices across 30 countries and employs over 10,000 people worldwide. With a presence in 100+ countries through its subsidiaries or associate companies. Piramal has been ranked among Forbes Asia’s 200 Best Under A Billion in 2019.
Business Verticals
PEL's Global Pharma division has a strong product portfolio of niche differentiated branded generics that are difficult to manufacture, sell, or distribute. Through its worldwide network of facilities, PEL's Contract Development and Manufacturing Organisation (CDMO) services segment provide end-to-end solutions across the drug life cycle.
The Indian consumer products division of PEL serves India’s self-care market. PEL's OTC portfolio includes 21 major pharmaceutical and personal care brands in diverse product categories such as Vitamins & Nutrition, Dermatological & Antacids, Analgesics, and Baby Care. PEL's Healthcare Insights & Analytics division is the world's leading provider of healthcare analytics data, insight products and services to the world's leading pharma, biotech and medical technology companies, allowing them to make informed business decisions.
PEL's financial services include wholesale lending, housing finance, and alternative asset management. Piramal Capital & Housing Finance Ltd, PEL's wholly-owned subsidiary, is registered as a housing finance company with National Housing Bank (NHB) and is involved in a variety of financial services businesses. It offers wholesale and retail funding opportunities across industries.
Company History
Piramal Enterprises was founded as Indian Schering Limited on April 26, 1947, by British Schering Ltd. With effect from September 27, 1979, the company's name was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd. Gujarat Glass Ltd (GGL) was acquired with the company on April 1, 1990. The new formulation plant in Pithampur, Madhya Pradesh, was inaugurated in 1991. After a year, in 1992, the company established a second formulation plant in Pithampur, Madhya Pradesh, with cutting-edge manufacturing facilities. The company's name changed from 'Nicholas Laboratories Ltd' to 'Nicholas Piramal India Ltd' on December 2, 1992.
Milestones
1988
Entered the pharmaceutical industry with the purchase of Nicholas Laboratories.
A series of mergers and acquisitions, joint ventures and alliances, and organic initiatives.
2010
Over two decades, they built a leading Indian pharmaceutical company.
The Domestic Formulations business was sold to Abbott in 2010 for USD 3.8 billion. Diagnostic Services were sold to Super Religare Laboratories.
From 2020 onwards
Multiple capital raise initiatives helped to strengthen the balance sheet.
Through the sale of DRG and the exit of Shriram Transport, the organization structure was simplified.
Subsidized the pharmaceutical businesses and raised new capital from Carlyle Transforming Financial Services with the DHFL acquisition to deliver long-term growth and profitability.
- NSE Symbol
- PEL
- BSE Symbol
- 500302
- ISIN
- INE140A01024
Similar Stocks to Piramal Enterprises
Piramal Enterprises FAQs
Piramal Enterprises share price is ₹1,107 As on 28 December, 2024 | 01:04
The Market Cap of Piramal Enterprises is ₹24960.4 Cr As on 28 December, 2024 | 01:04
The P/E ratio of Piramal Enterprises is -13.2 As on 28 December, 2024 | 01:04
The PB ratio of Piramal Enterprises is 0.9 As on 28 December, 2024 | 01:04
Piramal Enterprises Ltd recorded net sales of INR 13993 crores in the year ending March 2022.
Piramal Enterprises Ltd stock may be a good buy according to market analysts considering meaningful inroads into Retail led by mortgages and small-term loans via digital alliance.
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.